-
Mashup Score: 1
The FDA has approved olutasidenib (Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation as detected by an FDA-approved test.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0New IDH1 Inhibitor Wins FDA Approval for Acute Myeloid Leukemia - 1 year(s) ago
Olutasidenib led to a 35% response rate in a study of adults with previously treated AML
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
#FDAApproved ✅ IDH1 inhibitor #olutasidenib (#Rezlidhia) for relapsed or refractory AML. Rezlidhia demonstrated "a CR+CRh rate of 35% in patients, with over 90% of those responders in complete remission." -@GCC_Cortes of @GACancerCenter & @RigelPharma: https://t.co/ENcyZpZ5SD
-
-
Mashup Score: 1
Mirvetuximab soravtansine produced responses in almost a third of patients in pivotal trial
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
✅#FDAApproved: The FDA granted accelerated approval for the antibody-drug conjugate (ADC) mirvetuximab soravtansine (Elahere) for folate receptor α (FRα)-positive platinum-resistant #ovariancancer. https://t.co/cdWfFumdX2
-
-
Mashup Score: 0
Bispecific antibody achieved durable responses in a majority of heavily pretreated patients
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
#FDAApproved ✅ Treatment options for relapsed/refractory #multiplemyeloma continue to expand with FDA's #acceleratedapproval of #teclistamab (#Tecvayli). "These are remarkable results," said principal investigator @szusmani of @MSKCancerCenter. https://t.co/Rso0M3wBLA
-
-
Mashup Score: 7
The FDA has granted accelerated approval to teclistamab-cqyv (Tecvayli) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 previous lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
BREAKING: @US_FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma #mmsm #FDAApproved #oncology https://t.co/gkXYeGEsMb https://t.co/dmzCFjN8t5
-
-
Mashup Score: 0FDA Approves At-Home Furosemide for Heart Failure - 2 year(s) ago
Strong diuretic to become available outside the hospital setting
Source: www.medpagetoday.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
✅ #FDAApproved the first #furosemide (#Furoscix) formulation for subcutaneous self-administration by patients with #congestiveheartfailure, @scPharmaUSA announced. https://t.co/IZxdBiaKym
-
-
Mashup Score: 0
Significant improvement in itch and nodules at 24 weeks seen in two randomized trials
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
#FDAApproved ✅ Affecting about 75k Americans, this #skincondition causes persistent itch associated w/ nodular skin lesions. #Dupilumab (#Dupixent) is the 1st FDA-approved treatment w/ an indication for #PrurigoNodularis, @SanofiUS & @Regeneron announced: https://t.co/G4RSdE7pfy
-
-
Mashup Score: 0
Selpercatinib approved for advanced or metastatic solid tumors that progress on systemic therapy
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
✅ #FDAApproved: The @FDA granted accelerated approval to #selpercatinib (#Retevmo) for adults with locally advanced or metastatic solid tumors associated with RET gene fusions: https://t.co/JBZ7qPeCSi @VivekSubbiah
-
-
Mashup Score: 0FDA approves Rolvedon to reduce infection incidence when taking certain anticancer drugs - 2 year(s) ago
The FDA approved eflapegrastim-xnst injection to reduce incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies taking certain anticancer drugs, according to a company-issued press release.The approval of eflapegrastim-xnst (Spectrum Pharmaceuticals), a long-active granulocyte colony-stimulating factor with a novel formulation, applies to patients who
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@US_FDA approves Rolvedon to reduce infection incidence among adults taking certain anticancer drugs. https://t.co/T18SlCickD #FDAApproved #MedEd #MedEducation #MedTwitter #OncoAlert @sppirx
-
-
Mashup Score: 0
PODCAST Ophthalmology Journal dives deep into research articles, editorials, and more from the American Academy of Ophthalmology’s journal family: Ophthalmology, Ophthalmology Retina, Ophthalmology Glaucoma, and Ophthalmology Science. Join our rotating hosts of social media editors every other Thursday as they interview authors and editors about their groundbreaking…
Source: www.aao.orgCategories: Latest Headlines, OphthalmologyTweet-
New #OphthalmologyJournal #Podcast! @DrLorraineEyeMD interviews Michael Snyder on the #FDAapproved #CustomFlex Artificial #Iris device https://t.co/rs9xvIbS7T https://t.co/b3BloblmmY
-
ICYMI: The FDA has approved olutasidenib (Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation as detected by an FDA-approved test. #fdaapproved #oncology #leusm https://t.co/PSZ5Zp2vPb